Risk Stratification and Patient Trajectories in CAPS: The Important Role of the Autoinflammatory Disease Damage Index
4 affiliations
- 1Division of Pediatric Rheumatology and Autoinflammation Reference Center Tuebingen (arcT), Department of Pediatrics, University Children’s Hospital Tuebingen, Hoppe-Seyler-Strasse 1, 72076 Tuebingen, Germany
- 2European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases, ERN-RITA Coordinating Office, 3584 CX Utrecht, The Netherlands
- 3Rheumatology, Department of Pediatrics, Alberta Children’s Hospital (ACH), ACH Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB T3B 6A8, Canada
- 4Children’s Health Ireland, D12 N512 Dublin, Ireland
Abstract
Objective: Persistent inflammation in cryopyrin-associated periodic syndromes (CAPS) causes cumulative organ damage, quantified by the Autoinflammatory Disease Damage Index (ADDI). We evaluated the ADDI for risk stratification and assessed risk trajectories under treat-to-target (T2T) management. Methods: This retrospective analysis of prospectively collected single-centre registry data included consecutive paediatric patients diagnosed with CAPS between 2007 and 2024 with ≥24 months of follow-up. The ADDI was scored at the initial damage assessment, 6 months after the first assessment at our centre (baseline), and at the last visit, and patients were assigned to predefined mild, moderate and severe risk strata. Results: Of 71 patients (56% female; median follow-up 7 years), 23 (32%) had damage at the initial damage assessment, most frequently auditory (24%), developmental (14%) and ocular (11%). ADDI scores were higher in patients with pathogenic/likely pathogenic NLRP3 variants (median 2 vs. 0; p < 0.001) and increased across phenotypes (FCAS 0, MWS 0, CINCA/NOMID 9; p < 0.001). Risk strata remained unchanged in 69 patients (97%). Two children progressed from mild to moderate risk due to progression of sensorineural hearing loss; both were non-adherent to anti-IL-1 therapy, and neither showed increased disease activity at the last visit. Conclusions: In paediatric CAPS, early cumulative damage was common and associated with phenotype and NLRP3 variant pathogenicity. Under T2T management, ADDI risk strata remained largely stable. Although based on few patients, the damage progression captured by the ADDI, but not reflected by conventional disease activity measures at the time of assessment, supports a complementary role of the ADDI in longitudinal outcome monitoring.
Related
- Inferring flux-based metabolic fingerprints from gene expression to predict drug response and facilitate patient stratification
- A Mechanistic Framework for Somatic Mosaicism in Autoinflammatory Diseases Beyond Mendelian Inheritance
- Deep learning-based analysis reveals patient-level cancer therapy trajectories using single-cell PBMC chromatin images
- Exploring clinically anchored therapeutic stratification and tumor-stroma heterogeneity using patient-derived 3D bioprinted primary liver cancer models.
- Biomarker discovery and patient stratification in pancreatic cancer using incomplete multi-omics data
BibTeX
@article{satirer2026risk,
title = {{Risk Stratification and Patient Trajectories in CAPS: The Important Role of the Autoinflammatory Disease Damage Index}},
author = {Özlem Satirer and Marie Bogenschütz and Susanne M. Benseler and Jasmin B. Kuemmerle-Deschner},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218232},
url = {https://www.mdpi.com/2077-0383/15/21/8232},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Risk Stratification and Patient Trajectories in CAPS: The Important Role of the Autoinflammatory Disease Damage Index
AU - Özlem Satirer
AU - Marie Bogenschütz
AU - Susanne M. Benseler
AU - Jasmin B. Kuemmerle-Deschner
PY - 2026
DA - 2026/10/22
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218232
UR - https://www.mdpi.com/2077-0383/15/21/8232
AB - Objective: Persistent inflammation in cryopyrin-associated periodic syndromes (CAPS) causes cumulative organ damage, quantified by the Autoinflammatory Disease Damage Index (ADDI). We evaluated the ADDI for risk stratification and assessed risk trajectories under treat-to-target (T2T) management. Methods: This retrospective analysis of prospectively collected single-centre registry data included consecutive paediatric patients diagnosed with CAPS between 2007 and 2024 with ≥24 months of follow-up. The ADDI was scored at the initial damage assessment, 6 months after the first assessment at our centre (baseline), and at the last visit, and patients were assigned to predefined mild, moderate and severe risk strata. Results: Of 71 patients (56% female; median follow-up 7 years), 23 (32%) had damage at the initial damage assessment, most frequently auditory (24%), developmental (14%) and ocular (11%). ADDI scores were higher in patients with pathogenic/likely pathogenic NLRP3 variants (median 2 vs. 0; p < 0.001) and increased across phenotypes (FCAS 0, MWS 0, CINCA/NOMID 9; p < 0.001). Risk strata remained unchanged in 69 patients (97%). Two children progressed from mild to moderate risk due to progression of sensorineural hearing loss; both were non-adherent to anti-IL-1 therapy, and neither showed increased disease activity at the last visit. Conclusions: In paediatric CAPS, early cumulative damage was common and associated with phenotype and NLRP3 variant pathogenicity. Under T2T management, ADDI risk strata remained largely stable. Although based on few patients, the damage progression captured by the ADDI, but not reflected by conventional disease activity measures at the time of assessment, supports a complementary role of the ADDI in longitudinal outcome monitoring.
SN - 2077-0383
ER -